Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 14 | 2021 | 345 | 4.850 |
Why?
|
| Anti-Asthmatic Agents | 5 | 2019 | 56 | 2.550 |
Why?
|
| Emergency Service, Hospital | 9 | 2021 | 711 | 1.910 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2017 | 186 | 1.660 |
Why?
|
| Ambulatory Care | 2 | 2020 | 340 | 1.090 |
Why?
|
| Hospitalization | 7 | 2021 | 978 | 1.070 |
Why?
|
| Child | 19 | 2021 | 6405 | 1.010 |
Why?
|
| Child, Preschool | 15 | 2020 | 3187 | 0.960 |
Why?
|
| Community-Acquired Infections | 2 | 2015 | 46 | 0.930 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 378 | 0.930 |
Why?
|
| Pneumonia | 2 | 2015 | 110 | 0.890 |
Why?
|
| Dexamethasone | 3 | 2014 | 150 | 0.870 |
Why?
|
| Bacteremia | 2 | 2015 | 155 | 0.820 |
Why?
|
| Medicaid | 5 | 2021 | 302 | 0.820 |
Why?
|
| Administration, Inhalation | 4 | 2017 | 187 | 0.740 |
Why?
|
| Tonsillectomy | 1 | 2021 | 69 | 0.700 |
Why?
|
| Adolescent | 15 | 2020 | 8912 | 0.680 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 504 | 0.660 |
Why?
|
| Patient Preference | 1 | 2019 | 57 | 0.630 |
Why?
|
| Parents | 2 | 2019 | 312 | 0.610 |
Why?
|
| Retrospective Studies | 10 | 2021 | 7277 | 0.570 |
Why?
|
| Mobile Applications | 1 | 2019 | 138 | 0.560 |
Why?
|
| Infant | 7 | 2020 | 2891 | 0.550 |
Why?
|
| Aftercare | 1 | 2017 | 114 | 0.530 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 468 | 0.520 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 49 | 0.510 |
Why?
|
| Medication Adherence | 1 | 2019 | 335 | 0.510 |
Why?
|
| Drug Prescriptions | 2 | 2014 | 135 | 0.510 |
Why?
|
| Chronic Disease | 1 | 2020 | 1330 | 0.510 |
Why?
|
| Logistic Models | 6 | 2020 | 1420 | 0.490 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 127 | 0.470 |
Why?
|
| Hospitals, Rural | 1 | 2014 | 43 | 0.460 |
Why?
|
| Guideline Adherence | 2 | 2013 | 287 | 0.460 |
Why?
|
| Glucocorticoids | 2 | 2012 | 222 | 0.460 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2013 | 1 | 0.460 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2013 | 1 | 0.460 |
Why?
|
| Electronic Health Records | 2 | 2014 | 374 | 0.450 |
Why?
|
| Prednisone | 2 | 2012 | 104 | 0.440 |
Why?
|
| Cost-Benefit Analysis | 6 | 2015 | 504 | 0.430 |
Why?
|
| Circumcision, Male | 1 | 2012 | 12 | 0.430 |
Why?
|
| Humans | 26 | 2021 | 68618 | 0.420 |
Why?
|
| United States | 10 | 2021 | 7367 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 234 | 0.410 |
Why?
|
| Length of Stay | 1 | 2015 | 780 | 0.390 |
Why?
|
| Outpatients | 1 | 2011 | 127 | 0.370 |
Why?
|
| Public Health | 1 | 2012 | 201 | 0.370 |
Why?
|
| Cost of Illness | 1 | 2012 | 206 | 0.370 |
Why?
|
| Quality Improvement | 1 | 2014 | 413 | 0.350 |
Why?
|
| Female | 17 | 2021 | 38074 | 0.350 |
Why?
|
| Male | 16 | 2021 | 37321 | 0.350 |
Why?
|
| Hospitals, Pediatric | 3 | 2015 | 114 | 0.330 |
Why?
|
| Patient Compliance | 1 | 2011 | 402 | 0.320 |
Why?
|
| HIV Infections | 2 | 2012 | 791 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 767 | 0.300 |
Why?
|
| Health Care Costs | 3 | 2018 | 346 | 0.300 |
Why?
|
| Insurance, Health | 2 | 2020 | 201 | 0.290 |
Why?
|
| Pediatrics | 3 | 2013 | 341 | 0.250 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 191 | 0.230 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1046 | 0.210 |
Why?
|
| South Carolina | 3 | 2014 | 2752 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2018 | 7029 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2020 | 2358 | 0.190 |
Why?
|
| Nasal Surgical Procedures | 1 | 2020 | 21 | 0.180 |
Why?
|
| Respiratory System | 1 | 2020 | 28 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 772 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 117 | 0.170 |
Why?
|
| Foreign Bodies | 1 | 2020 | 58 | 0.170 |
Why?
|
| Racism | 1 | 2020 | 59 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2020 | 99 | 0.170 |
Why?
|
| Grounded Theory | 1 | 2019 | 20 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2020 | 622 | 0.160 |
Why?
|
| Reminder Systems | 1 | 2019 | 39 | 0.160 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 142 | 0.160 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 165 | 0.160 |
Why?
|
| Bronchoscopy | 1 | 2020 | 147 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 39 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2019 | 392 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 5717 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 1026 | 0.150 |
Why?
|
| Mass Screening | 2 | 2014 | 843 | 0.150 |
Why?
|
| Endoscopy | 1 | 2020 | 464 | 0.140 |
Why?
|
| Drug Utilization | 2 | 2014 | 119 | 0.140 |
Why?
|
| HIV Seropositivity | 2 | 2014 | 66 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2020 | 880 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2020 | 1615 | 0.130 |
Why?
|
| Colorado | 1 | 2015 | 26 | 0.130 |
Why?
|
| Adult | 5 | 2020 | 21403 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 89 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.120 |
Why?
|
| Magnesium | 1 | 2015 | 110 | 0.120 |
Why?
|
| Steroids | 1 | 2015 | 84 | 0.120 |
Why?
|
| Metronidazole | 1 | 2014 | 28 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 1753 | 0.120 |
Why?
|
| Trichomonas vaginalis | 1 | 2014 | 22 | 0.120 |
Why?
|
| Trichomonas Vaginitis | 1 | 2014 | 25 | 0.120 |
Why?
|
| Leukotriene Antagonists | 1 | 2013 | 13 | 0.120 |
Why?
|
| STAT6 Transcription Factor | 1 | 2013 | 11 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 12 | 0.110 |
Why?
|
| Surface Plasmon Resonance | 1 | 2013 | 50 | 0.110 |
Why?
|
| Interleukin-4 | 1 | 2013 | 69 | 0.110 |
Why?
|
| Protein Structure, Secondary | 1 | 2013 | 136 | 0.110 |
Why?
|
| Streptococcus pyogenes | 1 | 2013 | 20 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2013 | 32 | 0.110 |
Why?
|
| Colony Count, Microbial | 1 | 2013 | 77 | 0.110 |
Why?
|
| Physician's Role | 1 | 2013 | 116 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2013 | 239 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 166 | 0.100 |
Why?
|
| Decision Trees | 1 | 2012 | 74 | 0.100 |
Why?
|
| Binding Sites | 1 | 2013 | 631 | 0.100 |
Why?
|
| Attitude | 1 | 2012 | 121 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 170 | 0.100 |
Why?
|
| Anus Neoplasms | 1 | 2012 | 37 | 0.100 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 47 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2012 | 411 | 0.100 |
Why?
|
| Office Visits | 1 | 2011 | 83 | 0.090 |
Why?
|
| Escherichia coli | 1 | 2013 | 368 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2013 | 431 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2013 | 384 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 442 | 0.090 |
Why?
|
| Physicians | 1 | 2013 | 324 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1851 | 0.090 |
Why?
|
| Cell Line | 1 | 2013 | 1752 | 0.080 |
Why?
|
| Risk Factors | 2 | 2020 | 5731 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2012 | 448 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 3259 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2014 | 2455 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 1293 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 454 | 0.070 |
Why?
|
| Middle Aged | 3 | 2013 | 21147 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2013 | 2689 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 1426 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2279 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 95 | 0.040 |
Why?
|
| Incidence | 2 | 2014 | 1603 | 0.040 |
Why?
|
| Reoperation | 1 | 2020 | 467 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 106 | 0.030 |
Why?
|
| Hospital Departments | 1 | 2013 | 15 | 0.030 |
Why?
|
| Meaningful Use | 1 | 2013 | 21 | 0.030 |
Why?
|
| Prednisolone | 1 | 2012 | 23 | 0.030 |
Why?
|
| Proctoscopy | 1 | 2012 | 4 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 277 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 53 | 0.030 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 320 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 579 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 369 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 248 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 800 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1038 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 2007 | 0.020 |
Why?
|